Continuation of the nuMoM2b Heart Health Study
At a glance
Conditions
Where it's being run
14 sites across 8 statesStudy leadership
- George Saade, MD · PRINCIPAL_INVESTIGATOR · Old Dominion University
- Phillip Greenland, MD · PRINCIPAL_INVESTIGATOR · Northwestern University
- Rebecca McNeil, PhD · PRINCIPAL_INVESTIGATOR · RTI International
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Incidence of hypertension (130/80 mmHg)Assessed during the HHS2 in-person visit, 8-16 years after the index pregnancy.
Measured blood pressure \> 130/80 mmHg, use of antihypertensive medication, or self-report of a hypertension clinical diagnosis
- Incidence of diabetesAssessed during the HHS2 in-person visit, 8-16 years after the index pregnancy.
Measured hemoglobin A1c GE 6.5%, fasting blood glucose GE 126 mg/dL, use of blood sugar lowering medication, or self-report of a diabetes clinical diagnosis
- Incidence of obesityAssessed during the HHS2 in-person visit, 8-16 years after the index pregnancy.
Measured BMI GE 30 kg/m\^2
- Incidence of metabolic syndromeAssessed during the HHS2 in-person visit, 8-16 years after the index pregnancy.
Per the American Heart Association standard definition: Any three of the following five - 1) waist circumference \> 35 inches (88 cm) for non-Asians and \> 31.5 inches (80 cm) for Asians; 2) triglycerides \> 150 mg/dL or medication treatment for high triglycerides; 3) high density lipoprotein (HDL) \< 50 mg/dL or medication treatment for low HDL; 4) a serum glucose ≥ 100 mg/dL or a diagnosis of diabetes mellitus; 5) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg, or medication treatment for hypertension.